Repealing Brand Drug ‘Copay Coupons’ Ban Increases Costs by $750 Million
June 14, 2012
(Washington, DC)— If Massachusetts legislators vote to repeal the state ban on prescription brand drug “copay coupon” programs, costs...
Filter by:
Drug Coupons & Assistance Programs
Filter by Year:Clear Filters- Press Releases
- Biosimilars
- Drug Abuse Prevention
- Drug Adherence Programs
- Drug Cost Management
- Drug Coupons & Assistance Programs
- Drug Coverage Mandates
- Drug Price Negotiations & Rebates
- Employers, Unions, & Insurers
- FEHBP Program
- Formulary Design
- Fraud, Waste, & Abuse
- Generic Drug Utilization
- Health Insurance Marketplace (ACA)
- Home Delivery of Drugs
- Mark Merritt
- Medicaid
- Medicare Part D
- Patient Cost Sharing
- Pharmacy Networks
- Pharmacy Reimbursement & Contracting
- REMS Management
- Specialty Benefit Design
- Specialty Pharmacies
- Specialty Pharmacy Networks
- TRICARE
- Value & Outcomes-Based Contracting
5 Questions for Brand Drug Copay Coupon Defenders
January 26, 2012
Prescription copay coupon marketing programs, which lure insured consumers toward more expensive brands, will increase costs by $32 billion over...